Public-registry site landscape for NCT03239392, a LGL Leukemia study sponsored by Bioniz Therapeutics. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03239392 (registry record) |
| Sponsor | Bioniz Therapeutics |
| Condition(s) | LGL Leukemia; CTCL |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 4 |
| Site countries | United States |
Eichor generates a preliminary site-risk snapshot for NCT03239392 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →